Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00290953 | Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide | PHASE2 | COMPLETED | 432 | — | — | Oct 1, 2002 | Mar 1, 2006 | Dec 23, 2008 | 14 | Argentina, Australia +12 |
| Name | Type | Description |
|---|---|---|
| SR48692 | DRUG | - |
Inclusion Criteria: * Pathological diagnosis: Histologically or cytologically proven SCLC. * Disease stage: extensive stage * Measurable disease by the RECIST criteria is required. Lesions that are present in previously irradiated area are non-measurable unless they have appeared or progressed sinc...